Atherosclerosis Burdens in Diabetes Mellitus: Assessment by PET Imaging

Høilund‐Carlsen, Poul Flemming; Piri, Reza; Madsen, Per; Revheim, Mona‐Elisabeth; Werner, Thomas; Alavi, Abass; Gerke, Oke; Sturek, Michael

doi:10.3390/ijms231810268

Cited by 10 publications

(4 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, there is an inability to define emia, hypoxia, and subsequently leading to diabetic foot [24,25]. Hyperlipidemia can further reduce blood flow to the feet by exacerbating vascular atherosclerosis, thereby worsening the condition of diabetic foot [26,27]. However, the author found that fasting blood glucose and blood cell analysis were not risk factors for diabetic foot, which may be associated with their higher variability and differ from the conclusions of other studies, possibly due to the sample size.…”

Section: Discussionmentioning

confidence: 79%

Design and clinical application of a risk prediction model for diabetic foot

Yang

2024

Am J Transl Res

View full text Add to dashboard Cite

Objective: To construct and evaluate a nomogram prediction model for the risk of diabetic foot in patients with type 2 diabetes based on their clinical data, and to assist clinical healthcare professionals in identifying highrisk factors and developing targeted intervention measures. Methods: We retrospectively collected clinical data from 478 hospitalized patients with type 2 diabetes at the First Affiliated Hospital of Shantou University Medical College from January 2019 to December 2021. The patients were divided into a diabetic foot group (n=312) and a non-diabetic foot group (n=166) based on whether they had diabetic foot. The baseline data of both groups were collected. Univariate and multivariate analyses as well as logistic regression analysis were conducted to explore the risk factors for diabetic foot. A nomogram prediction model was established using the package "rms" version 4.3. The model was internally validated using the area under the receiver operating characteristic curve (AUC). Additionally, the decision curve analysis (DCA) was performed to evaluate the performance of the nomogram model. Results: The results from the logistic regression analysis revealed that being male, smoking, duration of diabetes, glycated hemoglobin, hyperlipidemia, and atherosclerosis were influencing factors for diabetic foot (all P<0.05). The AUC of the model in predicting diabetic foot was 0.804, with a sensitivity of 75.3% and specificity of 74.4%. Harrell's C-index of the nomogram prediction model for diabetic foot was 0.804 (95% CI: 0.762-0.844), with a threshold value of >0.675. The DCA findings demonstrated that the nomogram model provided a net clinical benefit. Conclusion: The nomogram prediction model constructed in this study showed good predictive performance and can provide a basis for clinical workers to prevent and intervene in diabetic foot, thereby improving the overall diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 79%

Design and clinical application of a risk prediction model for diabetic foot

Yang

2024

Am J Transl Res

View full text Add to dashboard Cite

show abstract

“…The "Imaging" study focused on the early phase of atherosclerosis, which is characterized by inflammation detected on PET imaging. PET has been used extensively to explore early atherosclerosis in heterozygous familial hypercholesterolemia (HeFH) 15 , diabetes mellitus 16 , and the general population. 17 PET scans provide insights into the pathophysiology of early plaque formation and inflammation.…”

Section: Discussionmentioning

confidence: 99%

Tracking Early Atherosclerosis by Audiometry; A Review of Studies in a High Risk Population

Greenwald,

Ball

2023

MRAJ

View full text Add to dashboard Cite

Objectives: Increasing levels of atherosclerosis correlate with increasing degrees of hearing loss. We hypothesized that arterial inflammation observed on FDG-PET/CT scans correlates with audiogram test results and that Major Adverse Cardiovascular Events occur in subjects with severe hearing loss (>40 dB). Methods: A FDG-PET/CT imaging prospective study was performed in an NIH trial including 115 rheumatoid arthritis subjects over age 50 without a history of cardiovascular disease, and 22 subjects were selected for concurrent audiograms. All were evaluated by 18-fluorodeoxyglucose positron emission tomography computed tomography scans and audiogram tests, at baseline and 6 months. In our institution, 320 similar RA subjects were identified over age 50 with no prior cardiovascular disease and chart review completed for 10 years to evaluate MACE occurrence. Audiograms were available for the 320 retrospective patients. Results: In the imaging study, at baseline there was a strong correlation between arterial inflammation on FDG-PET/CT and hearing test results (p<0.002). Hearing loss over 30 decibels was strongly associated with high levels of inflammation on FDG-PET/CT imaging. In the larger 320 retrospective group, there were 11 MACE (3.4%) in the 10 years period which occurred in subjects with even greater hearing loss (average measurement was over 50 dB). Conclusion: Atherosclerosis was identified through FDG-PET/CT imaging studies and hearing tests. All MACE occurred in patients with significant hearing loss. Testing comprised a unique population with systemic inflammation from RA. If confirmed in larger studies in the general population, audiograms might provide a cost- effective substitute for FDG-PET/CT imaging and provide potentially an improved individual patient cardiovascular risk assessment. Audiograms may infer cardiovascular

show abstract

“…Any therapeutical intervention relying on GPR119 levels will benefit from PET imaging. Thus, our new strategy of PET imaging with [ 18 F]KSS3 may eventually provide real-time quantification 38 of GPR119 expression and distribution to enable biological, mechanistic, and therapeutic studies of T2DM. Our PET radioligand could be invaluable for GPR119 agonist drug development by establishing target engagement, dosing, metabolic stability, occupancy, and safety profiles.…”

Section: Parallel Artificial Membrane Permeability Assay (Pampa) For ...mentioning

confidence: 99%

First GPR119 PET Imaging Ligand: Synthesis, Radiochemistry, and Preliminary Evaluations

Bansode,

Damuka,

Bashetti

et al. 2023

J. Med. Chem.

View full text Add to dashboard Cite

G-protein-coupled receptor 119 (GPR119) has emerged as a promising target for treating type 2 diabetes mellitus. Activating GPR119 improves glucose homeostasis, while suppressing appetite and weight gain. Measuring GPR119 levels in vivo could significantly advance GPR119-based drug development strategies including target engagement, occupancy, and distribution studies. To date, no positron emission tomography (PET) ligands are available to image GPR119. In this paper, we report the synthesis, radiolabeling, and preliminary biological evaluations of a novel PET radiotracer [18F]KSS3 to image GPR119. PET imaging will provide information on GPR119 changes with diabetic glycemic loads and the efficacy of GPR119 agonists as antidiabetic drugs. Our results demonstrate [18F]KSS3’s high radiochemical purity, specific activity, cellular uptake, and in vivo and ex vivo uptake in pancreas, liver, and gut regions, with high GPR119 expression. Cell pretreatment with nonradioactive KSS3, rodent PET imaging, biodistribution, and autoradiography studies showed significant blocking in the pancreas showing [18F]KSS3’s high specificity.

show abstract

Atherosclerosis Burdens in Diabetes Mellitus: Assessment by PET Imaging

Cited by 10 publications

References 77 publications

Design and clinical application of a risk prediction model for diabetic foot

Design and clinical application of a risk prediction model for diabetic foot

Tracking Early Atherosclerosis by Audiometry; A Review of Studies in a High Risk Population

First GPR119 PET Imaging Ligand: Synthesis, Radiochemistry, and Preliminary Evaluations

Contact Info

Product

Resources

About